不对称二甲基精氨酸
脑脊液
内科学
一氧化氮
内分泌学
阿尔茨海默病
一氧化氮合酶
病态的
过氧亚硝酸盐
认知功能衰退
医学
化学
疾病
痴呆
精氨酸
超氧化物
生物化学
氨基酸
酶
作者
Sönke Arlt,Friedrich Schulze,Martin Eichenlaub,Renke Maas,Jan Lehmbeck,Edzard Schwedhelm,Holger Jahn,Rainer H. Böger
出处
期刊:Dementia and Geriatric Cognitive Disorders
[S. Karger AG]
日期:2008-01-01
卷期号:26 (1): 58-64
被引量:48
摘要
Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase and may alter NO production during pathological conditions. Concerning Alzheimer's disease (AD), there are reports on altered cerebral NO metabolism, but only few studies on ADMA concentrations in plasma and cerebrospinal fluid (CSF).We assessed plasma ADMA in 80 AD patients and 80 age- and gender-matched controls and CSF ADMA in a subgroup of 53 AD patients and 20 controls.ADMA plasma concentrations were increased, while CSF ADMA concentrations were decreased in AD patients. There was a significant association between decreasing CSF ADMA levels and the severity of cognitive impairment.Elevated ADMA in plasma might be a contributing factor for AD through alterations of NO metabolism, for example decreased cerebral microperfusion, while decreased levels of CSF ADMA might lead to a cerebral increase of NO, peroxynitrite production and oxidative protein damage. Our study reveals different mechanisms of plasma and CSF ADMA regulation, both potentially contributing to AD pathology.
科研通智能强力驱动
Strongly Powered by AbleSci AI